Research on ibogaine suggests meaningful reductions in opioid withdrawal severity and drug use in the months following treatment, with some studies reporting abstinence rates of 50–80% at one month and declining but still notable rates at twelve months. Clinic-reported outcomes vary widely depending on patient population, follow-up protocols, and the conditions being treated. No large-scale randomized controlled trial has been completed yet.

What Do Peer-Reviewed Studies Actually Show?

The most cited evidence comes from observational studies and case series rather than gold-standard randomized controlled trials (RCTs). Key findings include:

  • Brown & Alper (2018): A retrospective analysis of 88 participants receiving ibogaine for opioid use disorder found that 80% reported a significant reduction in withdrawal symptoms immediately after treatment. At one-month follow-up, roughly 50% reported abstinence from opioids.
  • Noller et al. (2018): A twelve-month New Zealand observational study found that participants treated with ibogaine reported sustained reductions in opioid use. At twelve months, approximately 33% remained abstinent, while others showed significantly reduced use compared to baseline.
  • Mash et al. (ongoing Panama cohort): Dr. Deborah Mash's long-running research at licensed offshore clinics has reported that a single ibogaine session eliminated or dramatically reduced opioid withdrawal in the majority of participants, with roughly 30% maintaining abstinence at six months without additional sessions.
  • Ona et al. systematic review (2022): A Frontiers in Pharmacology systematic review covering 14 studies concluded that ibogaine consistently reduces opioid craving and withdrawal intensity, but noted that study heterogeneity and small sample sizes limit firm conclusions.

Researchers consistently flag the same caveat: most participants sought treatment voluntarily, creating selection bias. People motivated enough to travel abroad for ibogaine may have higher baseline motivation for recovery, inflating apparent success rates.

How Do Ibogaine Clinics Define and Report Success?

Clinic-reported outcomes are not standardized, which makes direct comparison difficult. Reputable clinics operating legally in Mexico, Portugal, South Africa, and other jurisdictions typically track:

  • Acute withdrawal resolution: Most clinics report 70–90% of opioid-dependent patients complete detox without requiring supplemental opioids.
  • 30-day abstinence: Figures commonly cited range from 50–75%, though follow-up methodology varies enormously.
  • 6- and 12-month abstinence: Harder to track due to patients returning home. Estimates from clinics with active aftercare programs range from 25–50% full abstinence, with many more reporting reduced use.
  • Patient-reported well-being: Many clinics also survey depression, anxiety, and quality-of-life scores. Improvements of 30–60% on validated scales like PHQ-9 and GAD-7 are commonly reported in clinic literature, though independent verification is rare.

Clinics without structured aftercare programs tend to report lower long-term outcomes, reinforcing the view that ibogaine is most effective as the beginning of a recovery process rather than a standalone cure.

What Does the Veterans' TBI Study Add?

A landmark 2024 study published in Nature Medicine (Cherian et al.) examined ibogaine combined with magnesium in 30 U.S. special operations veterans with traumatic brain injuries (TBI) at a licensed clinic in Mexico. Results at one month post-treatment included:

  • A 88% average reduction in PTSD symptom severity (PCL-5 scale)
  • An 87% average reduction in depression symptom severity (BDI scale)
  • An 81% average reduction in anxiety (SAI scale)
  • Significant improvements in cognitive function and disability scores

This study is widely cited because of its rigorous pre/post measurement design and independent academic analysis through Stanford University. However, it was not a placebo-controlled RCT, and the sample was small and highly specific. It has nonetheless accelerated regulatory and research interest, contributing to expanded clinical trials currently recruiting.

Safety Context: Ibogaine carries serious cardiac risks, including QT interval prolongation that can lead to fatal arrhythmia. A 2021 review identified at least 19 fatalities associated with ibogaine administration globally. Success rate data must be understood alongside this risk profile. Medical screening, cardiac monitoring, and qualified oversight are non-negotiable in any responsible treatment setting. Ibogaine is Schedule I in the United States; legal treatment currently requires travel to licensed international clinics.

Are Randomized Controlled Trials Underway?

The field is moving toward higher-quality evidence. MAPS (Multidisciplinary Association for Psychedelic Studies) is sponsoring a Phase 2 clinical trial (NCT05765994) examining ibogaine for opioid use disorder. Additional trials are being designed or recruiting for PTSD and alcohol use disorder. The FDA has not granted ibogaine Breakthrough Therapy Designation as of 2026, though advocacy and legislative efforts — including the TREAT Veterans Act — are actively pushing for expanded research pathways. Australia's Therapeutic Goods Administration (TGA) granted ibogaine a scheduling review in 2024, and researchers there are pursuing RCT frameworks.

Until RCT data is published, all success rate figures should be treated as preliminary, reflecting real but uncontrolled signals rather than definitive efficacy benchmarks.

How Do Ibogaine Outcomes Compare to Conventional Treatments?

Context matters when evaluating ibogaine success rates. For comparison:

  • Methadone maintenance: Highly effective at reducing illicit opioid use while on medication, but discontinuation rates are high and it does not address underlying trauma drivers of addiction.
  • Buprenorphine/naloxone (Suboxone): Strong evidence for reducing overdose risk and illicit use; 12-month retention rates in treatment range from 40–60% in real-world settings.
  • Naltrexone (Vivitrol): Effective when adherent, but adherence at 6 months drops significantly without intensive support — roughly 20–30% in many studies.
  • Residential rehab (28-day): Abstinence rates at one year without ongoing treatment average 20–30% across meta-analyses.

Ibogaine's reported 30–50% twelve-month abstinence rates — if validated by RCTs — would be competitive. However, its risk profile, cost (typically $5,000–$15,000 USD), and legal barriers make it fundamentally different in accessibility terms.

What Factors Most Influence Individual Outcomes?

Researchers and clinicians identify several variables consistently linked to better outcomes:

  • Aftercare and integration support: Participants with structured psychotherapy, support groups, or coaching post-treatment consistently show better long-term outcomes across all studies.
  • Motivation and readiness for change: Self-reported readiness scores at intake correlate with abstinence at follow-up.
  • Single substance vs. polysubstance use: Opioid-only dependence shows the strongest response; polysubstance use complicates outcomes.
  • Number of treatment sessions: Some patients receive booster sessions; multi-session protocols show modestly better long-term data in clinic reports.
  • Trauma history and mental health support: The Nature Medicine TBI study underlines that addressing co-occurring PTSD and trauma may be integral to durable recovery.

Frequently Asked Questions

Current observational research suggests approximately 50–75% of patients report abstinence at one month post-treatment, declining to roughly 25–50% at twelve months depending on aftercare. These figures come from uncontrolled studies and should be considered preliminary until RCT data is available.
No responsible researcher or clinician frames it that way. Ibogaine can dramatically interrupt the physical withdrawal cycle and create a psychological window of openness, but long-term recovery depends heavily on integration support, therapy, and lifestyle changes afterward. Clinics with aftercare programs consistently report better outcomes than those offering ibogaine alone.
Direct comparison is premature because ibogaine lacks RCT data while methadone and buprenorphine have extensive trial evidence. Philosophically they differ too — MOUD (medication-assisted treatment) reduces harm while continuing medication, whereas ibogaine aims at acute interruption followed by abstinence. Neither approach is universally superior; individual circumstances determine appropriateness.
Treat clinic self-reported figures with healthy skepticism. There is no standardized reporting requirement, no independent verification, and strong marketing incentives to emphasize positive outcomes. Clinics with published peer-reviewed follow-up data, third-party audits, or academic partnerships offer more credible numbers than marketing brochures alone.
The evidence base for alcohol and stimulant use disorders is much thinner than for opioids. Case reports and small series suggest some patients report reduced cravings, but the dramatic withdrawal-interruption effect seen with opioids is not replicated. Alcohol withdrawal also carries its own medical risks that complicate ibogaine use. Dedicated trials for these conditions are in early stages.
The 2024 Cherian et al. study in Nature Medicine found average reductions of 88% in PTSD symptoms, 87% in depression, and 81% in anxiety one month after a single magnesium-ibogaine session in 30 veterans with TBI. While striking, the study was small, uncontrolled, and specific to TBI veterans — results should not be generalized to the broader population without further research.
Ibogaine is a Schedule I controlled substance in the United States, meaning it is illegal to manufacture, distribute, or possess outside of DEA-approved research contexts. Americans seeking ibogaine treatment currently do so at licensed clinics in countries including Mexico, Portugal, the Netherlands, and South Africa. Legislation like the TREAT Veterans Act is working to expand legal research access domestically.

Getting Accurate Information Before Making Decisions

Success rate statistics — whether from journals or clinic websites — are only one part of the picture. Anyone seriously researching ibogaine treatment should consult with an addiction medicine physician to evaluate whether it is medically appropriate, undergo cardiac screening (ECG and electrolyte panel), and seek clinics with documented medical oversight, transparent follow-up protocols, and structured aftercare. The Global Ibogaine Therapy Alliance (GITA) publishes clinical guidelines that offer a useful benchmark for evaluating clinic standards. Because ibogaine is Schedule I in the US, any treatment requires international travel; understanding the legal landscape before making arrangements is essential.

Informational only. Not medical or legal advice. Ibogaine is Schedule I in the US. Consult qualified professionals.